{
  "docId": "019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "docSlug": "439c1d555948cf75a9b0a41f96565740",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 29,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a chevron-based process flow to represent maturity stages: Proven, Under Evaluation, and Future.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e0bc-7319-b2fa-5eeb46bcf895/20",
  "deckHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "deckJsonHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895.json",
  "deckAnchorHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Three-stage chevron process flow: PROVEN, UNDER EVALUATION, FUTURE",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fa889df-636a-4e0c-96ae-3e92abcd606b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "PROVEN: Oral Formulations of Anti-Infectives (MAT2203, Remdesivir, MAT2501), Oral Formulations of Chemotherapeutics (Docetaxel)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "249af4d4-4e46-42e0-b2b8-c533296838f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.58,
        "y": 0.35
      },
      "kind": "list",
      "text": "FUTURE: Potential Therapeutic Applications (Infection, Inflammation, Oncology)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9266c1e-4cbb-4612-ac30-1f659ad3ddd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.31,
        "y": 0.45
      },
      "kind": "list",
      "text": "UNDER EVALUATION: Intracellular Delivery of Nucleic Acids (siRNA, ASO)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f45517b6-d246-4669-a61f-40d0fb7faed0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.32,
        "x": 0.34,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "* Key Areas of Focus for Internal LNC Oral Small Oligonucleotides",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1168d58b-c299-442d-a16b-1f3f948f9bff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.1,
        "y": 0.18
      },
      "kind": "title",
      "text": "Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3e5bf8b-f0e9-4389-8d1e-d1955ff1efc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.52,
        "x": 0.048,
        "y": 0.06
      },
      "kind": "title",
      "text": "Unlocking the Full Potential of the LNC Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4d3f1d1-07d9-430a-88d5-02fddf52dd8f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "2254d416-e4e7-4c5d-b3d5-fba06b035b51",
      "evidence": "Chevron-based progression of therapeutic applications over time/maturity",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}